Effective treatment of
allergic diseases
such as asthma and atopic dermatitis

Airsonett, a leading Swedish MedTech company, has announced significant findings from an independent technical study evaluating its Temperature-controlled Laminar Airflow (TLA) technology.
The study was presented at the EACCI Congress in Valencia, Spain, on May 31st. It demonstrates the significant efficacy of Airsonett’s TLA technology in reducing airborne allergens such as cat dander, grass pollen, and house dust mite allergens in the breathing zone.

Christine is one of the first patients in Norway to receive Airsonett TLA treatment (Temperature-controlled Laminar Airflow) for her allergic disease. She has had asthma and allergies since preschool. With TLA treatment, she has gotten a new life. She is less ill and has a much better quality of life.

The Swedish MedTech company Airsonett’s treatment for severe allergic diseases, TLA, has been proven effective for patients with severe exacerbations (asthma flare-ups) and improving the quality of life while being cost-effective. That is the result of a new post hoc analysis of a previous study.

Fåhraeus Startup & Growth Fund joins as an owner of the Swedish Medtech company Airsonett, which is facing an international expansion. Airsonett has developed the patented method TLA, for effective treatment of severe allergic diseases, such as asthma and atopic eczema, with clean air.

Airsonett announced today a new observational study showing a significant effect of Airsonett TLA (Temperature-controlled Laminar Airflow) for treating adult atopic dermatitis (AD) patients. The proof-of-concept study is published in the Journal of the European Academy of Dermatology and Venereology.

Airsonett announced today that the company is expanding into the Italian market through a distributor partnership with INNOVACAREMD. The company will distribute Airsonett’s unique medical device for TLA treatment (Temperature-controlled Laminar Airflow), the patented and effective treatment of allergic diseases such as allergic asthma and atopic eczema.

Airsonett announced today a new publication: “Effect of nocturnal Temperature-controlled Laminar Airflow on the reduction of severe exacerbations in patients with severe allergic asthma: a meta-analysis”1

Airsonett announced today that the company’s novel and proprietary technology TLA (Tempera-ture-controlled Laminar Airflow) would be evaluated in the treatment of children with severe atopic eczema. Imperial College London UK will perform and sponsor the single centre, random-ized placebo-controlled study.